

**BLOOD LEAD IS A PREDICTOR OF
HOMOCYSTEINE LEVELS IN A POPULATION-
BASED STUDY OF OLDER ADULTS**

**Jyme H. Schafer, Thomas A. Glass, Joseph Bressler, Andrew
C. Todd, and Brian S. Schwartz**

doi:10.1289/ehp.7369 (available at <http://dx.doi.org/>)

Online 7 September 2004



**The National Institute of Environmental Health Sciences
National Institutes of Health
U.S. Department of Health and Human Services**

BLOOD LEAD IS A PREDICTOR OF HOMOCYSTEINE LEVELS IN A POPULATION-BASED STUDY OF OLDER ADULTS

Jyme H. Schafer,^{1,4} Thomas A. Glass,² Joseph Bressler,^{3,5,6} Andrew C. Todd,⁷ Brian S. Schwartz^{1,2,4}

Affiliations

Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland

¹ Department of Environmental Health Sciences, Division of Occupational and Environmental Health

² Department of Epidemiology

³ Department of Environmental Health Sciences, Division of Toxicological Sciences

Johns Hopkins University, School of Medicine, Baltimore, Maryland

⁴ Department of Medicine

⁵ Department of Neurology

Kennedy Krieger Institute, Baltimore, Maryland

⁶ Department of Neurotoxicology

Mount Sinai School of Medicine, New York, New York

⁷ Department of Community and Preventive Medicine

Reprint requests and correspondence to: Dr. Brian S. Schwartz, Johns Hopkins Bloomberg School of Public Health, Division of Occupational and Environmental Health, 615 North Wolfe Street, Room W7041, Baltimore, Maryland, 21205. Voice 410-955-4130; fax 410-955-1811; email bschwart@jhsph.edu.

Running head: BLOOD LEAD AND HOMOCYSTEINE

Key Words: homocysteine; blood lead; tibia lead; cross-sectional study

Grant support: This work was supported by R01 AG19604 (Dr. Schwartz).

Abbreviations: GED, graduate equivalency diploma; ALAD, δ -aminolevulinic acid dehydratase;

OR, odds ratio; MCP-1, monocyte chemoattractant protein-1; IL-8, interleukin-8

Outline of Section Headers

Abstract

Introduction

Methods

Results

Discussion

ABSTRACT

Lead and homocysteine are both associated with cardiovascular disease and cognitive dysfunction. The relations among blood lead, tibia lead, and homocysteine levels were evaluated by cross-sectional analysis of data among subjects in the Baltimore Memory Study, a longitudinal study of 1,140 50-70 year old randomly-selected residents in Baltimore City. Tibia lead was measured by ^{109}Cd K-shell X-ray fluorescence. The subject population had a mean (SD) age of 59.3 (5.9) years, and was 66.0% female, 53.9% white, and 41.4% black or African American. Mean (SD) blood lead, tibia lead, and homocysteine levels were 3.5 (2.4) $\mu\text{g/dL}$, 18.9 (12.5) $\mu\text{g/g}$, and 10.0 (4.1) $\mu\text{mol/L}$, respectively. In unadjusted analysis, blood lead and homocysteine were moderately correlated (Pearson's $r = 0.27$, $p < 0.01$). After adjustment for age, gender, race/ethnicity, educational level, tobacco and alcohol consumption, and body mass index using multiple linear regression, results revealed that homocysteine levels increased 0.35 $\mu\text{mol/L}$ per 1.0 $\mu\text{g/dL}$ increase in blood lead ($p < 0.01$). The relations of blood lead with homocysteine levels did not differ in subgroups distinguished by age, gender, or race/ethnicity. Tibia lead was modestly correlated with blood lead (Pearson's $r = 0.12$, $p < 0.01$) but was not associated with homocysteine levels. To our knowledge, these are the first data to reveal an association between blood lead and homocysteine. These results suggest that homocysteine could be a mechanism that underlies the effects of lead on the cardiovascular and central nervous systems, possibly offering new targets for intervention to prevent the long-term consequences of lead exposure.

INTRODUCTION

As a result of centuries of human use, lead is omnipresent in the environment. Commercial use of this substance continues even though its toxic effects have been recognized since ancient times (Nriagu 1983), and more recent studies report health effects associated with lower and lower lead doses (Canfield et al. 2003; Glenn et al. 2003; Nash et al. 2003; Schwartz et al. 2000). Lead is not rapidly cleared from the body; while the biological residence time of lead in blood is measured in days, the biological residence time of lead in bone is on the order of years to decades (Hu et al. 1998). In occupational and general population samples, low blood lead levels have been associated with increased blood pressure and elevated risk of hypertension, effects that may be progressive (Cheng et al. 2001; Glenn et al. 2003; Nash et al. 2003); increased circulatory and cardiovascular mortality (Lustberg and Silbergeld 2002); and progressive declines in cognitive function over time, even years after cessation of occupational exposure (Schwartz et al. 2000; Schwartz et al. 2004 b). One of the key remaining problems in the research of lead toxicity is that the mechanisms for these effects are not well understood.

Interestingly, homocysteine is also associated with cardiovascular disease and cognitive dysfunction (Dufouil et al. 2003; Homocysteine Collaboration 2002). Homocysteine is an independent risk factor for vaso-occlusive disease; elevated levels of homocysteine increase the risk of heart disease, stroke, and peripheral vascular disease and, perhaps through vascular mechanisms, cognitive dysfunction (Bautista et al. 2002; Dufouil et al. 2003; Homocysteine Collaboration 2002; Prins et al. 2002; Ravaglia et al 2003; Wald et al. 2002). Vascular damage by homocysteine may occur through impaired vascular endothelial and smooth muscle cell function (Rodrigo et al. 2003). The mechanisms of this impairment may involve inhibition of

nitric oxide synthesis, increased oxidative stress, proliferation of vascular smooth muscle cells, and altered elasticity of the vascular wall (Rodrigo et al. 2003).

Despite the similarities in these health effects, the relation of homocysteine and lead dose has not been previously examined. Herein, we report associations of blood lead, tibia lead, and homocysteine in a population-based study of 50 to 70 year olds in Baltimore. Participants were selected from the general population and most are without occupational lead exposure.

METHODS

Study Design

The Baltimore Memory Study, one of the National Institutes of Health's disparities initiative grants, is a multi-level cohort study of risk factors for cognitive decline in Baltimore City residents of targeted neighborhoods. The methods are described elsewhere (Schwartz et al. 2004a). The selected neighborhoods were chosen to provide areas with a broad range of socioeconomic status and large numbers of both whites and African Americans. A cross-sectional analysis of first visit data was performed.

Subject Selection and Recruitment

Sampling and recruitment has been previously described (Schwartz et al. 2004a). In brief, individual dwellings in the study area were linked to telephone numbers, and households with telephones were randomly selected for recruitment. Eligibility was then determined on 2,351 subjects (50-70 years old, living at selected household, lived in Baltimore at least five years) and of these subjects, 60.8% were scheduled for an enrollment visit. Of the 1,403 scheduled for an appointment, 1,140 (81.3%) were enrolled and subsequently tested. The study

was approved by the Committee for Human Research of the Johns Hopkins Bloomberg School of Public Health. All participants provided written, informed consent before testing and were paid \$50 for their participation.

Data Collection

All data were collected at the study clinic by trained research assistants. A structured interview included the following information: demographics, socioeconomic status (household income, household assets, occupational status, and educational attainment), medical history, smoking and alcohol history, and lead history. First and second visits were conducted between May 2001 and September 2002, and October 2002 and February 2004, respectively. A trained phlebotomist drew a 10 ml blood specimen into a red-top (no anti-coagulant) tube, which was clotted, centrifuged and stored at -20 °C within one hour. Samples were transported to the Johns Hopkins Bloomberg School of Public Health and stored at -70 °C. Serum homocysteine was measured by a commercial laboratory using fluorescence polarization immunoassay (Abbott AxSYM, Abbott Park, IL). The coefficients of variation for the quality control samples for three concentration levels were 3.64% (low range), 2.24% (mid range), and 2.32% (high range). Fasting was not requested of the subjects because study visits were scheduled at all times of the day for logistical reasons. The variability between fasting and non-fasting samples is not likely to exaggerate the association but instead would dampen it. Conditions that cause short-term fluctuations in homocysteine levels, such as protein intake, are not likely to be related to whole blood lead levels. Homocysteine was measured from a sample obtained at the first study visit in the majority of subjects; however, 254 subjects only provided plasma at the first visit so had serum obtained at the second visit for homocysteine measurement. Lead was measured in the metals laboratory of the Kennedy Krieger Institute (Baltimore) from the first study visit whole blood specimen using anodic stripping voltammetry (Schwartz et al., 2004 a). Tibia lead

concentration was measured at the second study visit by ^{109}Cd -induced K-shell X-ray fluorescence (XRF) using previously reported methods (Todd et al. 1992; Todd and McNeill 1993; Todd 2000; Todd et al. 2000). In this population of older adults without occupational lead exposure, tibia lead, which has a biological residence time of 25-30 years, should not have changed appreciably between the first and second study visits.

Statistical Methods

The main objectives of this analysis were to: 1) evaluate relations of blood lead and tibia lead levels with homocysteine, controlling for age, race/ethnicity, gender, and other potential confounding variables; and 2) to evaluate whether these relations were modified by age, gender, or race/ethnicity. Of the 1,140 persons enrolled at V1, 78 subjects were missing homocysteine, 10 were missing blood lead, 7 missing information on alcohol consumption, 6 on BMI, and one each for education and tobacco use. A total of 1,022 (89.6%) subjects completed the second study visit, so 82 participants were missing tibia lead data. Thus, in analyses with blood lead and tibia lead, 1,037 and 955 subjects were included, respectively. Subjects with missing homocysteine data were not statistically different on blood lead, age, or race/ethnicity. To minimize the influence of large tibia lead values, tibia lead was log-transformed before use in models. Negative values for tibia lead were converted to 0.1 before log-transformation. Associations with tibia lead were also examined non-parametrically, using a percentile transformation for tibia lead; results did not differ from those using the log-transformed tibia lead and are not reported.

Multiple linear regression was used to examine the relations of blood lead with homocysteine levels, controlling for covariates. Models were first constructed including known homocysteine covariates (e.g., age, gender, and race/ethnicity), then other potential confounding

variables were included in a forward stepwise fashion. Variables were retained in the final models if they were associated with homocysteine levels or significantly influenced the relation of blood or tibia lead with homocysteine (changed the lead coefficient by more than 10%). The final model included age, race/ethnicity, gender, educational level (four categories based on reported years of education and information on GED, training for trades, and additional educational certificates), alcohol (four categories based on the number of alcoholic drinks per month, with a drink being defined as one beer, one glass of wine, one wine cooler, one cocktail or one shot of liquor), smoking (four categories based on the number of cigarettes smoked per day), and body mass index (kg/m^2). Effect modification was evaluated by including cross-product terms in the model (e.g., to evaluate effect modification by race/ethnicity, a cross-product of race/ethnicity and blood lead was included in the model). All statistical analysis was performed using Stata version 8.0 (Stata Corporation, College Station, TX). Final models were checked for the assumptions of linear regression and model fit using influence diagnostic procedures, examination of residuals, and residual-residual plots.

RESULTS

Study subjects were 66.0% female, 41.4% non-Hispanic Black/African American, 53.9% non-Hispanic White or White/Native American, and had a mean (range) age of 59.3 (49 - 71) years. The mean (SD) blood lead and homocysteine levels were 3.5 (2.4) $\mu\text{g}/\text{dL}$ and 10.0 (4.1) $\mu\text{mol}/\text{L}$, respectively (Table 1). Subjects had a wide range of educational levels, smoking habits, and alcohol habits; in unadjusted analysis, these were differentially associated with blood lead and homocysteine levels, evaluated in quartiles (Tables 1 and 2). Using blood lead and homocysteine as continuous measures, in unadjusted analysis, these were moderately correlated,

with Pearson's $r = 0.27$ ($p < 0.01$). Blood lead and tibia lead levels were only modestly correlated (Pearson's $r = 0.11$, for the log transformed data [Figure 1], and $r = 0.12$ for the untransformed data, both p -values < 0.01).

Multiple linear regression was next used to evaluate predictors of homocysteine levels, controlling for covariates (Table 3 and Figure 2). Controlling for age, gender, race/ethnicity, smoking habits, alcohol habits, and educational level the results revealed that an increase of $1.0 \mu\text{g/dL}$ in blood lead was associated with an increase of $0.35 \mu\text{mol/L}$ in homocysteine levels (Figure 2; in the figure, but not the regression model, three large values for blood lead are removed so that the portion of the plot with the most data could be better visualized). As gender was strongly associated with both homocysteine and lead levels, separate models were next repeated in men and women (Table 3). The association was larger in males, with a $1.0 \mu\text{g/dL}$ increase in blood lead resulting in a $0.43 \mu\text{mol/L}$ increase in homocysteine, as compared to a $0.24 \mu\text{mol/L}$ increase for females, but this difference did not achieve statistical significance. Finally, there was no effect modification by gender or race/ethnicity on relations on blood lead and homocysteine levels (data not shown). Tibia lead was not associated with homocysteine levels, and addition of tibia lead to the models with blood lead did not change model fit or other coefficients.

To evaluate whether time of day influenced homocysteine levels, homocysteine was grouped in consecutive two-hour intervals based on time of phlebotomy. Control for time of day in the final regression model did not appreciably alter the association of blood lead and homocysteine levels. Additionally, because the first 254 subjects provided plasma, these subjects had blood redrawn at the second study visit to obtain serum. There was no difference in the mean homocysteine levels based on when the sample was obtained, and associations of blood lead with homocysteine did not vary by visit number.

DISCUSSION

To our knowledge, this is the first study to examine relations of blood lead and tibia lead with homocysteine levels. A significant association between blood lead and homocysteine was observed in an older, community-dwelling, adult, population-based sample in a major U.S. urban area after controlling for age, gender, race/ethnicity, alcohol intake, cigarette smoking, educational level, and body mass index. As previously observed, gender, age, and smoking a pack or greater per day were predictors of homocysteine levels (Jacques et al. 2001). Blood lead may influence homocysteine levels at very low dose levels (Figure 2). Among study subjects, blood lead levels were generally below 15 $\mu\text{g/dL}$, as expected in the general population. The study thus provides evidence of an association at low blood lead levels, but we were unable to characterize the association at higher blood lead levels. Though tibia lead was modestly associated with blood lead levels, it was neither a predictor of homocysteine levels nor a confounder of its relation with blood lead. Tibia lead levels were obtained at the second study visit. Subjects who did not complete the second study visit were more likely to be African American (52.4% v. 40.4%) and were slightly younger (58.5 v. 59.4) compared to subjects who completed the visit, but there was no difference in blood lead levels. We do not believe these small differences account for the contrasting associations of blood and tibia lead levels with homocysteine. Tibia lead, a measure of cortical bone lead, is generally a less important source of blood lead levels than is lead in trabecular bone, but is a good estimate of cumulative lead dose (Hu et al. 1998). The data suggest that bioavailable lead (i.e., blood lead) was a more important predictor of homocysteine levels than was cumulative lead dose (i.e., tibia lead).

Lead and homocysteine are both associated with an increased risk of cardiovascular disease and, possibly through vascular system mechanisms, central nervous system disease. In epidemiologic studies of central nervous system disease and cardiovascular outcomes, it is interesting to note that study results for lead parallel those for homocysteine. For example, in an occupational cohort of men with previous lead exposure (average 18 years prior), the systolic blood pressure increased on average 0.64 mm Hg (SE = 0.25) for every standard deviation increase in blood lead at baseline (Glenn et al. 2003). In a recent meta-analysis using data from 30 prospective or retrospective studies, a 25% lower homocysteine level (about 3 $\mu\text{mol/L}$) was associated with an approximately 11% (OR = 0.89, 95% CI = 0.83, 0.96) lower ischemic heart disease risk and a 19% (OR = 0.81, 95% CI = 0.69, 0.95) lower stroke risk (Homocysteine Collaboration 2002). Another meta-analysis of 20 prospective studies found that for an increase in serum homocysteine of 5 $\mu\text{mol/L}$ the odds ratio for ischemic heart disease was increased (OR = 1.32, 95% CI = 1.19-1.45), as was the odds ratio for stroke (OR = 1.59, 95% CI = 1.29-1.96) (Wald et al. 2002). Other studies support the similarities between the cardiovascular effects of lead and homocysteine (Bautista et al. 2002; Cheng et al. 2001; Kopp et al. 1988; Moller and Kristensen 1992; Nash et al. 2003; Pocock et al. 1988).

Both lead and homocysteine also have similar associations with central nervous system outcomes (ATSDR 1999; Balbus-Kornfeld et al. 1995; Dufouil et al. 2003; Prins et al. 2002; Ravaglia et al. 2003; Schwartz et al. 2000; Schwartz et al. 2001). There are suggestions that cognitive function is negatively impacted by elevated levels of either one. In a population-based study of 1,077 subjects, neurobehavioral test outcomes were lower in the upper quintile of homocysteine levels as compared with the lower four quintiles (Prins et al. 2002). The mean (SD) homocysteine level of this population was 11.5 (4.1) $\mu\text{mol/L}$, with the medians of the quintiles being 7.57 $\mu\text{mol/L}$, 9.12 $\mu\text{mol/L}$, 10.54 $\mu\text{mol/L}$, 12.47 $\mu\text{mol/L}$, and 16.34 $\mu\text{mol/L}$,

respectively. Comparison of the mean adjusted difference in test scores for subjects in the homocysteine upper quintile versus lower quintiles (looked at dichotomously) revealed a decrement in psychomotor speed (-0.26, 95 % CI = -0.37, 0.14), memory function (-0.13, 95% CI = -0.27, 0.01), and global cognitive function (-0.20, 95% CI = -0.30, 0.11). In a longitudinal study of 1,241 subjects (age 61 to 73 years), homocysteine levels above 15 $\mu\text{mol/L}$ conferred a 2.8 greater odds ($p < 0.05$) of cognitive decline compared with those subjects whose levels were below 10 $\mu\text{mol/L}$ (mean homocysteine level in this study was 12.2 $\mu\text{mol/L}$) (Dufouil et al. 2003). For lead, two recent longitudinal studies of occupational cohorts with current and/or past lead exposure were associated with longitudinal decline in cognitive function (Schwartz et al. 2000; Schwartz et al. 2004b). One of the studies consisted of former organolead workers (mean age 55.6 years), and utilized an extensive neurobehavioral test battery (Schwartz et al. 2000). In this study, an increase of 15.7 $\mu\text{g/g}$ of peak tibia lead (using back-extrapolation, the estimated tibia lead level at the end of employment in lead) was equivalent in its effects on annual test decline to five more years of age at baseline for six neurobehavioral tests of verbal memory and learning, executive abilities, and manual dexterity. Although blood lead, but not tibia lead, was associated with homocysteine levels, in this cross-sectional study we cannot be certain whether this means that recent lead exposure, mobilization of lead from bone, or both, are the likely source of lead that explains the association. With the growing evidence that lead may cause progressive elevations in blood pressure and declines in cognitive function over time (Glenn et al. 2003; Schwartz et al. 2000; Schwartz et al. 2001; Schwartz et al. 2004 b), this newly observed association between lead and homocysteine may offer new possibilities for preventive intervention.

There are several targets that lead could be acting upon that could explain this association. Lead can interact with proteins, in particular those with a sulfhydryl group (Goering

1993). An example of this occurrence is the inhibition of the δ -aminolevulinic acid dehydratase (ALAD) enzyme in the heme-synthesis pathway. ALAD is an octameric metalloenzyme which contains zinc in the activated state (Simons 1995). The active site for zinc-binding contains two cysteine residues. There is competitive inhibition between lead and zinc, with the ratio of the affinity of lead to zinc at the metal-binding site being about 25:1 for the 1-1 ALAD phenotype (Simons 1995). Such sulfhydryl binding by lead could be one mechanism that could account for the observed lead-homocysteine relation. In the metabolism of methionine, homocysteine can be remethylated by two different pathways or undergo transsulfuration to cysteine (Ueland and Refsum 1989). In the transsulfuration pathway there is a unique heme-containing enzyme, cystathionine β -synthase, that catalyses a pyridoxal 5'-phosphate dependent condensation of serine and homocysteine to give cystathionine (Banerjee et al. 2003). Work in the elucidation of the structure of cystathionine beta-synthase has revealed two sulfhydryl groups contained within the heme-binding site (Meier et al. 2001). Furthermore, homocysteine itself contains a sulfhydryl group, so if lead has an affinity for this sulfhydryl group the metabolism of homocysteine could be directly inhibited, leading to an accumulation of homocysteine.

It has been unclear whether homocysteine is a causative agent or only a marker of disease. In 1962, homocystinuria in mentally retarded children was discovered as an inborn error of metabolism (Carson and Neill 1962; Gerritsen et al. 1962). In 1964, cystathionine β -synthetase deficiency was demonstrated as a cause of this disorder (Mudd et al. 1964). The natural history of cystathionine β -synthetase deficiency includes a 50% chance of a vascular event (stroke, myocardial infarction, peripheral arterial or venous thrombosis) by age 30 years (Yap 2003). Recent experimental evidence suggests homocysteine to be a causal agent. Experimentation has shown isolated hyperhomocysteinemia to be atherogenic in cystathionine β -synthetase and apolipoprotein E double knock-out mice (Wang et al. 2003). Additionally,

homocysteine has been shown to stimulate the expression and secretion of biologically active monocyte chemoattractant protein-1 (MCP-1) and interleukin-8 (IL-8) in human monocytes (Zeng et al. 2003), two chemokines that are thought to be important to the development of atherosclerotic plaques.

In conclusion, blood lead was found to be associated with homocysteine levels in a large, general population sample. Though causality can not be determined from cross-sectional data, it is interesting to consider the possibility that this relation of lead and homocysteine could explain one of the mechanisms of the influence of lead on the central nervous and cardiovascular systems. Whether lead elevates homocysteine through enzyme inhibition, as earlier suggested, or conversely, that homocysteine elevates lead due to intravascular binding (homocysteine has a structure similar to dimercaptosuccinic acid [DMSA] and penicillamine, compounds that are known to bind lead), it is evident that the association exists at very low blood lead levels, and if the former mechanism is operative, is support for a biologic effect of lead at low levels. This knowledge may offer new targets for prevention of the progressive health effects of lead.

REFERENCES

- ATSDR 1999. Toxicologic Profile for lead (Update). Atlanta, GA: U. S. Department of Health and Human Services, Public Health Service.
- Balbus-Kornfeld JM, Stewart W, Bolla KI, Schwartz BS. 1995. Cumulative exposure to inorganic lead and neurobehavioural test performance in adults: an epidemiological review. *Occup Environ Med* 52:2-12.
- Banerjee R, Evande R, Kabil O, Ojha S, Taoka S. 2003. Reaction mechanism and regulation of cystathionine beta-synthase. *Biochim Biophys Acta* 1647:30-5.
- Bautista LE, Arenas IA, Penuela A, Martinez LX. 2002. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. *J Clin Epidemiol* 55:882-7.
- Canfield RL, Henderson CR, Jr., Cory-Slechta DA, Cox C, Jusko TA, Lanphear BP. 2003. Intellectual impairment in children with blood lead concentrations below 10 microg per deciliter. *N Engl J Med* 348:1517-26.
- Carson N, Neill D. 1962. Metabolic abnormalities detected in a survey of mentally backward individuals in northern Ireland. *Archives of Disease in Childhood* 37:505-513.
- Cheng Y, Schwartz J, Sparrow D, Aro A, Weiss ST, Hu H. 2001. Bone lead and blood lead levels in relation to baseline blood pressure and the prospective development of hypertension: the Normative Aging Study. *Am J Epidemiol* 153:164-71.
- Cleveland WS. 1979. Robust locally weighted regression and smoothing scatterplots. *J Am Stat Assoc* 74:829-836.
- Dufouil C, Alperovitch A, Ducros V, Tzourio C. 2003. Homocysteine, white matter hyperintensities, and cognition in healthy elderly people. *Ann Neurol* 53:214-21.

- Gerritsen T, Vaughn JG, Waisman HA. 1962. The identification of homocystine in the urine. *Biochem Biophys Res Commun* 9:493-6.
- Glenn BS, Stewart WF, Links JM, Todd A.C, Schwartz BS. 2003. The longitudinal association of lead with blood pressure. *Epidemiology* 14:30-6.
- Goering PL. 1993. Lead-Protein Interactions as a Basis for Lead Toxicity. *NeuroToxicology* 14:45-60.
- Homocysteine Collaboration, 2002. Homocysteine and Risk of Ischemic Heart Disease and Stroke: A meta-analysis. *JAMA* 288:2015-2022.
- Hu H, Rabinowitz M, Smith D. 1998. Bone lead as a biological marker in epidemiologic studies of chronic toxicity: conceptual paradigms. *Environ Health Perspect* 106:1-8.
- Jacques PF, Bostom AG, Wilson PW, Rich S, Rosenberg IH, Selhub J. 2001. Determinants of plasma total homocysteine concentration in the Framingham Offspring cohort. *Am J Clin Nutr* 73:613-21.
- Kopp SJ, Barron JT, Tow JP. 1988. Cardiovascular actions of lead and relationship to hypertension:A review. *Environ Health Perspect* 78:91-99.
- Lustberg M, Silbergeld, E. 2002. Blood lead levels and mortality. *Arch Intern Med* 162:2443-9.
- Meier M, Janosik M, Kery V, Kraus JP, Burkhard, P. 2001. Structure of human cystathionine beta-synthase: a unique pyridoxal 5'-phosphate-dependent heme protein. *Embo J* 20:3910-6.
- Moller L, Kristensen T. 1992. Blood lead as a cardiovascular risk factor. *American Journal of Epidemiology* 136:1091-1100.
- Mudd S, Finklestein J, Irreverre F, Laster L. 1964. Homocystinuria:an enzymatic defect. *Science* 143:1443-1445.

- Nash D, Lustberg M, Sherwin RW, Rubin RJ, Kaufmann R, Silbergeld E. 2003. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. *JAMA* 289:1523-1532.
- Nriagu JO. 1983. Lead and Lead Poisoning in Antiquity. John Wiley & Sons, inc, New York, 378-415.
- Pocock S, Shaper A, Ashby D, Delves H, Clayton B. 1988. The relationship between blood lead, blood pressure, stroke, and heart attacks in middle-aged British men. *Environ Health Perspect* 78:23-30.
- Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R, et al. 2002. Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. *Neurology* 59:1375-80.
- Ravaglia G, Forti P, Maioli F, Muscari A, Sacchetti L, Arnone G, et al. 2003. Homocysteine and cognitive function in healthy elderly community dwellers in Italy. *Am J Clin Nutr* 77:668-73.
- Rodrigo R, Passalacqua W, Araya J, Orellana M, Rivera G. 2003. Implications of oxidative stress and homocysteine in the pathophysiology of essential hypertension. *J Cardiovasc Pharmacol* 42:453-61.
- Schwartz BS, Stewart WF, Bolla KI, Simon PD, Bandeen-Roche K, Gordon PB, et al. 2000. Past adult lead exposure is associated with longitudinal decline in cognitive function. *Neurology* 55:1144-50.
- Schwartz BS, Lee BK, Lee GS, Stewart WF, Lee SS, Hwang KY, et al. 2001. Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with neurobehavioral test scores in South Korean lead workers. *Am J Epidemiol* 153:453-64.
- Schwartz BS, Stewart W, Hu H. 2002. Neurobehavioural testing in workers occupationally exposed to lead. *Occup Environ Med* 59:648-9.

- Schwartz BS, Glass T, Bolla K, Glass G, Stewart W, Todd A, et al. 2004a. Disparities in cognitive functioning by race/ethnicity in the Baltimore Memory Study. *Environ Health Perspect* 112:314-320.
- Schwartz BS, Lee B, Bandeen-Roche K, Stewart W, Bolla K, Links J, et al. 2004b. Lead dose is associated with longitudinal decline in neurobehavioral test scores in South Korean lead workers. *Epidemiology*, in press.
- Simons TJ. 1995. The affinity of human erythrocyte porphobilinogen synthase for Zn²⁺ and Pb²⁺. *Eur J Biochem* 234:178-83.
- Todd AC, McNeill FE, Palethorpe JE, Peach DE, Chettle DR, Tobin MJ, et al. 1992. In vivo X-ray fluorescence of lead in bone using K x-ray excitation with ¹⁰⁹Cd sources: radiation dosimetry studies. *Environ Res.* 57:117-132.
- Todd AC, McNeill FE. 1993. In vivo measurements of lead in bone using a Cd spot source. *Human Body Composition Studies*. New York, NY: Plenum Press, 299-302.
- Todd AC. 2000. Contamination of in vivo bone-lead measurements. *Phys Med Biol* 45:229-240.
- Todd AC, Carroll S, Godbold JH, Moshier EL, Khan FA. 2000. Variability in XRF-measured tibia lead levels. *Phys Med Biol* 45:3737-3748.
- Ueland PM, Refsum H. 1989. Plasma homocysteine, a risk factor for vascular disease: plasma levels in health, disease, and drug therapy. *J Lab Clin Med* 114:473-501.
- Wald DS, Law M, Morris JK. 2002. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. *BMJ* 325:1202-1206.
- Wang H, Jiang X, Yang F, Gaubatz JW, Ma L, Magera MJ, et al. 2003. Hyperhomocysteinemia accelerates atherosclerosis in cystathionine beta-synthase and apolipoprotein E double knock-out mice with and without dietary perturbation. *Blood* 101:3901-3907.

Yap S. 2003. Classical homocystinuria: vascular risk and its prevention. *J Inherit Metab Dis* 26:259-65.

Zeng X, Dai J, Remick DG, and Wang X. 2003. Homocysteine mediated expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human monocytes. *Circ Res* 93:311-20.

Table 1. Demographic Characteristics for the Inclusive Study Population and Lead Quartile Subsets, Baltimore Memory Study, 2001-2002

Characteristic	Blood Lead Quartile					p-value*
	Total (N = 1037)	Quartile 1 (N = 241)	Quartile 2 (N = 271)	Quartile 3 (N = 262)	Quartile 4 (N = 263)	
Blood lead level, mean (range) µg/dL	3.5 (0.1-27.3)	1.1 (0.1-1.9)	2.5 (2.0-3.0)	3.8 (3.1-4.4)	6.5 (4.5-27.3)	
Homocysteine, mean (SD) µmol/L	10.0 (4.1)	9.2 (3.4)	9.3 (3.5)	9.7 (3.6)	11.7 (5.1)	< 0.001
Age, mean (SD), years	59.3 (5.9)	59.3 (5.9)	59.3 (5.8)	59.0 (5.9)	59.8 (6.2)	0.52
Gender, % female	66.0	83.0	72.3	63.7	46.0	< 0.001
Race/Ethnicity, %						0.73
Non-Hispanic Black/African American	41.4	44.4	39.9	38.9	42.6	
Non-Hispanic White or Wht/Native American	53.9	49.4	55.7	56.1	54.0	
African American mixed race/ethnicity	2.7	2.9	3.0	3.1	1.9	
Asian, Hawaiian, Native American or other	2.0	3.3	1.4	1.9	1.5	
Body mass index, mean (SD) kg/m ²	29.8 (6.9)	31.5 (7.8)	30.7 (7.2)	28.8 (6.4)	28.3 (5.4)	< 0.001
Current cigarette use, %						0.008
None	79.8	85.9	80.8	82.4	70.7	

Less than ½ pack per day	5.6	3.7	7.8	3.5	7.2	
½ pack to less than a pack per day	7.6	4.2	5.9	8.0	12.2	
1 pack or greater per day	7.0	6.2	5.5	6.1	9.9	
Alcoholic beverage use, %						< 0.001
None	40.6	49.9	43.9	38.5	30.8	
< 4 per month	15.1	17.4	15.9	13.4	13.7	
4-8 per month	12.8	11.2	15.1	14.5	10.3	
>8 per month	31.5	21.6	25.1	33.6	45.2	
Education level, %						0.9
< High school or trade school	10.2	10.4	9.2	8.4	12.9	
Completed high school or trade school	41.7	41.5	43.2	41.2	40.7	
Some college or associates degree	5.9	6.2	6.3	6.1	4.9	
College degree or higher	42.2	41.9	41.3	44.3	41.5	

* P-value from chi-square for categorical variables or for continuous variables ANOVA F-test for linear trend across quartiles.

Table 2. Demographic Characteristics of Study Subjects by Homocysteine Quartiles, Baltimore Memory Study, 2001-2002.

Characteristic	Homocysteine Quartile				p-value*
	Quartile 1 (N = 245)	Quartile 2 (N = 269)	Quartile 3 (N = 259)	Quartile 4 (N = 264)	
Homocysteine, mean (range), $\mu\text{mol/L}$	6.6 (4.4-7.5)	8.3 (7.6-9.0)	10.0 (9.1-11.2)	15.0 (11.3-48.6)	
Blood lead level, mean (SD), $\mu\text{g/dL}$	2.8 (1.6)	3.2 (2.4)	3.7 (2.1)	4.4 (2.8)	< 0.001
Age, mean (SD), years	57.9 (5.5)	59.1 (5.8)	60.0 (6.0)	60.3 (6.2)	< 0.001
Gender, % female	87.8	69.1	59.5	48.9	< 0.001
Race/Ethnicity, %					0.001
Non-Hispanic Black/African American	39.2	36.1	42.9	47.4	
Non-Hispanic White or White/Native American	51.8	62.4	53.6	47.3	
African American/mixed race/ethnicity	5.7	0.4	2.7	2.3	
Asian, Hawaiian, Native American or other	3.3	1.1	0.8	3.0	
Body mass index, mean (SD), kg/m^2	29.2 (6.6)	29.6 (7.0)	30.2 (6.8)	30.2 (7.0)	0.27

Current cigarette use, %					0.001
None	84.5	85.1	79.1	70.8	
Less than ½ pack per day	6.1	4.5	4.2	7.6	
½ pack to less than a pack per day	5.3	5.6	9.7	9.9	
1 pack or greater per day	4.1	4.8	7.0	11.7	
Alcoholic beverage use, %					0.007
None	44.5	39.0	40.9	38.3	
< 4 per month	15.9	15.6	14.7	14.0	
4-8 per month	18.0	13.0	12.0	8.7	
>8 per month	21.6	32.4	32.4	39.0	
Education level, %					0.002
< High school or trade school	10.2	7.1	10.4	13.2	
Completed high school or trade school	39.6	37.2	40.9	48.9	
Some college or associates degree	6.5	3.7	8.1	5.3	
College degree or higher	43.7	52.0	40.6	32.6	

* P-value from chi-square for categorical variables or for continuous variables ANOVA F-test for linear trend across quartiles

Table 3. Predictors* of Homocysteine Levels in Subjects with Complete Data (N = 1,037), Baltimore Memory Study, 2001-2002.

	Total		Female		Male	
	(N = 1,037)		(N = 684)		(N = 353)	
	β (SE β)	p-value	β (SE β)	p-value	β (SE β)	p-value
Blood lead, µg/dL	0.35 (0.05)	< 0.001	0.24 (0.07)	0.001	0.43 (0.08)	< 0.001
Age, years	0.09 (0.02)	< 0.001	0.14 (0.02)	< 0.001	-0.02 (0.04)	0.61
Female	-1.46 (0.27)	< 0.001	_____		_____	
Body mass index, kg/m ²	0.05 (0.02)	0.004	0.05 (0.02)	0.02	0.09 (0.04)	0.03
Current cigarette use **						
Less than ½ pack per day	1.01 (0.53)	0.06	0.78 (0.62)	0.20	1.30 (0.96)	0.18
½ pack to less than a pack per day	1.53 (0.47)	0.001	2.05 (0.56)	< 0.001	0.80 (0.84)	0.35
One pack or greater per day	2.29 (0.49)	< 0.001	2.12 (0.60)	< 0.001	2.11 (0.83)	0.01

* Adjusted for variables in table as well as race/ethnicity (four categories), educational level (four categories), and alcohol consumption (none, < 4 per month, 4-8 per month, > 8 per month).

** Reference group is no current use

Figure Captions

Figure 1

Crude relation of \log_{10} -transformed blood lead levels and \log_{10} -transformed tibia lead levels for 955 participants in the Baltimore Memory Study. Dashed line represents a locally weighted smoothing fit (lowess bandwidth 0.10) (Cleveland 1979).

Figure 2

Smoothed plot of residuals of blood lead and homocysteine levels, controlling for covariates. Values were adjusted for age, gender, race/ethnicity, body mass index, educational level, and tobacco and alcohol use. The three data points with blood lead over 15 $\mu\text{g/dL}$ have been excluded from the plot (but not from the regression model) so that the portion of the plot with the most data could be more clearly visualized. The solid line is predicted linear fit and the dashed line is from a locally weighted smoothing fit (lowess bandwidth 0.05) (Cleveland 1979).




Figure 1




Figure 2